NFKB1 and colitis: Administration of MSCs-EVs down-regulated expression of NF-κB p65 and reduced production of NO, IL-1β and IL-18 in colon macrophages, resulting in alleviated 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis [26,27].